Health Care Industry

Industry: Email Alert RSS Feed
Comments

Taro's ANDA for Clobetasol Propionate Gel, 0.05% approved

Drug Store News, July 19, 1999

The Food and Drug Administration has approved Taro Pharmaceutical Industries' ANDA for Clobetasol Propionate Gel, 0.05%. The ANDA was submitted by the company's wholly owned subsidiary, Taro Pharmaceuticals Inc. of Ontario, Canada. Taro's Clobetasol Propionate Gel is classified as a very high potency topical corticosteroid indicated for the treatment of moderate to severe dermatologic conditions.

More Articles of Interest

Clobetasol Gel is bioequivalent to Glaxo Wellcome's Temovate(r) Gel. The product is the newest addition to the company's line of generic Clobetasol products, including Clobetasol cream, ointment and solution.

COPYRIGHT 1999 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement

Brought to you by CBS MoneyWatch.com

advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here

Content provided in partnership with Thompson Gale

Presented by American Express